RHON-KLINIKUM AG (RHK) AI Stock Analysis

RHON-KLINIKUM AG

(XETRA:RHK)

Select Model

Rating:59Neutral

Price Target:EUR 15.00▲(4.17% Upside)

Action:reiterated

Date:08/06/26

The score is driven primarily by solid balance-sheet strength, offset by deteriorating profitability and weaker cash generation in the latest year. Technical indicators add a bearish near-term signal (negative MACD and price below key moving averages), while valuation is neutral with a moderate P/E and a modest dividend yield.

Positive Factors

Conservative Balance SheetLow leverage and declining debt give RHÖN-KLINIKUM financial resilience in a regulated care environment. The sizeable, rising equity base provides a substantial cushion, supports continued hospital operations, and preserves flexibility to fund obligations or selective investment.

Negative Factors

Sharp EBIT DeclineThe steep EBIT decline while revenue increased signals substantial cost pressure or other operating headwinds. Such weak profit conversion reduces resilience, limits internally generated funding, and makes future earnings more sensitive to changes in expenses and reimbursement economics.

RHON-KLINIKUM AG (RHK) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 963.91M
Dividend Yield: 1.39%
Average Volume (3M): 5,240
Price to Earnings (P/E): 22.5
Beta (1Y): -0.00
Revenue Growth: 4.91%
EPS Growth: 11.71%
Country: Germany
Employees: 19,120
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

RHON-KLINIKUM AG Business Overview & Revenue Model

Company Description

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, delivers extensive healthcare services across Germany, encompassing inpatient, day-patient, and outpatient treatment models. The company's hospitals provide a broad spectrum of medical...

How the Company Makes Money

RHÖN-KLINIKUM AG primarily makes money by providing medical services through the hospitals and healthcare facilities it operates and receiving reimbursement for those services. Revenue is generated largely from (1) inpatient acute care treatments (e....

RHON-KLINIKUM AG Financial Statement Overview

Summary

Strong, conservatively financed balance sheet (low leverage and rising equity) supports stability, but operating performance has weakened: 2025 EBIT dropped sharply despite higher revenue and 2025 cash flow deteriorated (free cash flow turned negative). Overall financial risk looks moderate-to-low, with earnings and cash conversion as the main concerns.

Income Statement

62Positive

Balance Sheet

82Very Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.73B	1.94B	1.60B	1.73B	1.45B	1.40B
Gross Profit	-24.83M	167.75M	171.82M	202.88M	999.52M	182.63M
EBITDA	121.03M	69.40M	122.20M	116.58M	107.22M	100.76M
Net Income	42.09M	34.47M	43.35M	38.71M	25.14M	28.30M
Balance Sheet
Total Assets	1.83B	1.82B	1.86B	1.77B	1.70B	1.67B
Cash, Cash Equivalents and Short-Term Investments	556.55M	329.85M	409.46M	342.84M	296.33M	292.12M
Total Debt	121.88M	122.17M	149.60M	149.84M	158.20M	159.76M
Total Liabilities	466.89M	467.50M	530.51M	490.30M	453.51M	440.82M
Stockholders Equity	1.33B	1.32B	1.30B	1.25B	1.22B	1.20B
Cash Flow
Free Cash Flow	0	-34.60M	57.20M	46.20M	-16.90M	19.70M
Operating Cash Flow	0	64.50M	127.60M	109.00M	60.30M	97.50M
Investing Cash Flow	0	-132.10M	-50.40M	40.90M	-105.20M	-58.30M
Financing Cash Flow	0	-42.00M	-3.30M	-21.20M	-4.10M	-3.90M

RHON-KLINIKUM AG Technical Analysis

Technical Analysis SentimentPositive

Last Price14.40

Price Trends

50DMA14.48Negative

100DMA13.96Positive

200DMA13.24Positive

Market Momentum

MACD-0.00Positive

RSI48.24Neutral

STOCH25.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RHK, the sentiment is Positive. The current price of 14.40 is below the 20-day moving average (MA) of 14.46, below the 50-day MA of 14.48, and above the 200-day MA of 13.24, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 25.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:RHK.

RHON-KLINIKUM AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:RHK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:M12	79Outperform	EUR 344.06M	17.94	16.58%	6.13%	-27.50%	13.64%
DE:FME	72Outperform	EUR 10.73B	12.17	7.21%	3.69%	-0.47%	48.60%
DE:LIK	67Neutral	EUR 153.00M	27.60	22.18%	1.96%	35.46%	17.88%
DE:MED	64Neutral	EUR 251.75M	8.72	11.54%	0.75%	2.94%	-14.28%
DE:RHK	59Neutral	EUR 963.91M	22.50	3.18%	1.39%	4.91%	11.71%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:MAK	47Neutral	EUR 18.98M	-1.39	16.80%	―	2.73%	-1.80%

* General Sector Average

Performance Comparison

DE:RHK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:RHK	RHON-KLINIKUM AG	14.40	2.49	20.95%
DE:FME	Fresenius Medical Care AG & Co. KGaA	40.40	-3.51	-8.00%
DE:MED	MEDICLIN AG	5.30	1.68	46.37%
DE:MAK	MATERNUS-Kliniken AG	0.91	-0.14	-12.98%
DE:LIK	Limes Schlosskliniken AG	510.00	158.82	45.22%
DE:M12	M1 Kliniken AG	19.56	5.41	38.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

RHON-KLINIKUM AG AI Stock Analysis